Stephen Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics, and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Ferdinandos Skoulidis et al. published in Nature Medicine:
“Report in Nature Medicine from Ferdinandos Skoulidis on molecular determinants of efficacy with sotorasib in KRAS G12C NSCLC. TTF1 expression, NRF2 activation, and KEAP1 and ATM mutations were relevant. Can ctDNA clearance be used as an early pharmacodynamic marker?
Title: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Authors: Ferdinandos Skoulidis, Bob T. Li, Adrianus Johannes de Langen, David S. Hong, Herve Lena, Juergen Wolf, Grace K. Dy, Alessandra Curioni Fontecedro, Pascale Tomasini, Vamsidhar Velcheti, Anthonie J. van der Wekken, Christophe Dooms, Luis Paz-Ares Rodriguez, Giannis Mountzios, Adrian Sacher, Ernest Nadal, Sebastien Couraud, Sang-We Kim, Kenneth O’Byrne, Danilo Rocco, Ryo Toyozawa, Izabela Chmielewska, Colin R. Lindsay, Antreas Hindoyan, Lata Mukundan, Tomasz Wilmanski, Abraham Anderson, Christine Ardito-Abraham, Amrita Pati, Anita Reddy, Bhakti Mehta, Martin Schuler
You can read the Full Article in Nature Medicine.
Read the post on “New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer” in OncoDaily.
More posts featuring Stephen V Liu.
